Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more
Korea Bio-Gen Co.Ltd (318000) - Net Assets
Latest net assets as of September 2025: ₩46.23 Billion KRW
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has net assets worth ₩46.23 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩50.60 Billion) and total liabilities (₩4.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩46.23 Billion |
| % of Total Assets | 91.35% |
| Annual Growth Rate | 25.96% |
| 5-Year Change | 59.47% |
| 10-Year Change | N/A |
| Growth Volatility | 42.45 |
Korea Bio-Gen Co.Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Korea Bio-Gen Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Korea Bio-Gen Co.Ltd (2017–2024)
The table below shows the annual net assets of Korea Bio-Gen Co.Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩44.91 Billion | +6.80% |
| 2023-12-31 | ₩42.05 Billion | +20.34% |
| 2022-12-31 | ₩34.95 Billion | +10.55% |
| 2021-12-31 | ₩31.61 Billion | +12.24% |
| 2020-12-31 | ₩28.16 Billion | +9.65% |
| 2019-12-31 | ₩25.69 Billion | +134.08% |
| 2018-12-31 | ₩10.97 Billion | +22.92% |
| 2017-12-31 | ₩8.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Korea Bio-Gen Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 199.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩23.27 Billion | 51.81% |
| Common Stock | ₩1.75 Billion | 3.89% |
| Other Components | ₩19.90 Billion | 44.30% |
| Total Equity | ₩44.91 Billion | 100.00% |
Korea Bio-Gen Co.Ltd Competitors by Market Cap
The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Impresa SGPS S.A.
LSE:0M5U
|
$15.58 Million |
|
Awaysis Capital Inc
PINK:AWCA
|
$15.58 Million |
|
Pro Inside Public Company Limited
BK:PIS
|
$15.58 Million |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
$15.58 Million |
|
Eminent Gold Corp
OTCQB:EMGDF
|
$15.58 Million |
|
SPECO Ltd
KQ:013810
|
$15.58 Million |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
$15.57 Million |
|
REDCO PRP GROUP LTD -05
F:8KI
|
$15.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Korea Bio-Gen Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 42,053,864,770 to 44,912,890,190, a change of 2,859,025,420 (6.8%).
- Net income of 3,766,347,400 contributed positively to equity growth.
- Dividend payments of 869,936,100 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.77 Billion | +8.39% |
| Dividends Paid | ₩869.94 Million | -1.94% |
| Other Changes | ₩-37.39 Million | -0.08% |
| Total Change | ₩- | 6.80% |
Book Value vs Market Value Analysis
This analysis compares Korea Bio-Gen Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.01x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4057.56 | ₩4105.00 | x |
| 2018-12-31 | ₩4987.67 | ₩4105.00 | x |
| 2019-12-31 | ₩3159.38 | ₩4105.00 | x |
| 2020-12-31 | ₩3484.95 | ₩4105.00 | x |
| 2021-12-31 | ₩3903.79 | ₩4105.00 | x |
| 2022-12-31 | ₩4287.59 | ₩4105.00 | x |
| 2023-12-31 | ₩4834.13 | ₩4105.00 | x |
| 2024-12-31 | ₩5162.78 | ₩4105.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Korea Bio-Gen Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.39%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.12%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 1.15x
- Recent ROE (8.39%) is below the historical average (10.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 18.39% | 11.39% | 0.86x | 1.88x | ₩748.75 Million |
| 2018 | 19.41% | 12.96% | 0.83x | 1.80x | ₩1.03 Billion |
| 2019 | -5.47% | -7.58% | 0.66x | 1.10x | ₩-3.97 Billion |
| 2020 | 11.09% | 15.78% | 0.64x | 1.10x | ₩306.45 Million |
| 2021 | 12.67% | 14.72% | 0.65x | 1.33x | ₩842.51 Million |
| 2022 | 9.31% | 13.36% | 0.57x | 1.23x | ₩-242.14 Million |
| 2023 | 10.90% | 21.23% | 0.47x | 1.09x | ₩378.06 Million |
| 2024 | 8.39% | 15.12% | 0.48x | 1.15x | ₩-724.94 Million |
Industry Comparison
This section compares Korea Bio-Gen Co.Ltd's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $729,340,395,312
- Average return on equity (ROE) among peers: 5.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Korea Bio-Gen Co.Ltd (318000) | ₩46.23 Billion | 18.39% | 0.09x | $15.58 Million |
| DL Holdings CO. LTD. (000210) | $4.53 Trillion | 19.10% | 0.84x | $381.57 Million |
| Norooholdings (000320) | $402.45 Billion | 6.30% | 1.12x | $45.80 Million |
| Noroo Holdings Co Ltd (000325) | $583.54 Billion | 0.27% | 0.81x | $60.77 Million |
| Samhwa Paint (000390) | $299.72 Billion | 1.87% | 0.96x | $86.24 Million |
| Kangnam Jevisco Co Ltd (000860) | $366.15 Billion | 10.97% | 0.26x | $58.42 Million |
| Paik Kwang Ind (001340) | $204.57 Billion | 3.85% | 1.06x | $113.44 Million |
| Bo Lak (002760) | $43.76 Billion | 2.53% | 0.22x | $30.02 Million |
| Songwon Industrial (004430) | $543.25 Billion | 13.30% | 1.05x | $79.87 Million |
| Cho Kwang Pain (004910) | $172.73 Billion | -1.34% | 0.81x | $17.90 Million |
| Cosmoam&T (005070) | $147.00 Billion | -3.99% | 0.78x | $305.37 Million |